查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1612696

黏液囊炎治疗市场：按类型、药物类型、最终用户划分 - 全球预测 2025-2030

Bursitis Treatment Market by Type (Acute Bursitis, Chronic Bursitis), Drug Type (Medication, Physical Therapy), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

黏液囊炎治疗市场2023年估值为78.1亿美元，预计到2024年将达到81.4亿美元，复合年增长率为4.58%，到2030年将达到106.9亿美元。

黏液囊炎治疗市场有多种旨在缓解与黏液囊炎（缓衝关节附近的骨骼、肌腱、肌肉等的微小充满液体的囊）相关的发炎和疼痛的治疗方法。对黏液囊炎治疗的需求源于需要透过控制疼痛和防止关节进一步损伤来维持患者的活动能力和生活品质。治疗方法包括非类固醇消炎剂(NSAID) 和皮质类固醇注射等药物治疗，以及严重病例的物理治疗和手术。最终使用范围主要是医疗保健环境，例如医院、诊所、整形外科和物理治疗专业中心。

主要市场统计
基准年[2023] 78.1亿美元
预计年份 [2024] 81.4亿美元
预测年份 [2030] 106.9亿美元
复合年增长率（%） 4.58%

在市场成长方面，生活方式相关疾病的增加、老年人口的增加以及公众对肌肉骨骼健康意识的提高正在推动对有效黏液囊炎治疗的需求。最新的机会包括先进生物疗法和微创外科手术的开发，它们在疗效和患者康復时间方面提供了有希望的好处。透过遗传和生物标记研究的进步实现的个人化医疗创新也可能提供标靶治疗方案，精确满足个别患者的需求。

然而，市场成长受到先进治疗的高成本以及长期药物治疗的潜在副作用等挑战的阻碍。低收入地区获得医疗服务的机会有限进一步限制了市场扩张。此外，监管障碍和药物核准缓慢可能会减缓新疗法的推出。

创新和研究成熟的领域包括增强药物输送系统以提高靶向性和功效、开发具有成本效益的生技药品、用于监测和管理黏液囊炎症状的可穿戴设备以及数位健康解决方案的整合。透过人体工学教育和早期疗育策略来关注预防保健也将成为业务成长的关键槓桿。该市场呈现出动态的特点，其特点是技术的快速进步以及治疗和管理策略中多学科方法的日益整合。

市场动态：快速发展的黏液囊炎治疗市场的关键市场洞察

供应和需求的动态交互作用正在改变黏液囊炎治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球肌肉骨骼疾病的发生率不断上升
    • 意识的提高加上医疗基础设施投资的增加
  • 市场限制因素
    • 政府对药品核准的严格规定
  • 市场机会
    • 黏液囊炎诊断工具和治疗方案的进展
    • 配方开发持续创新
  • 市场挑战
    • 诊断复杂且缺乏报销政策

波特的五力：驾驭黏液囊炎治疗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解黏液囊炎治疗市场的外部影响

外部宏观环境因素在塑造黏液囊炎治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解黏液囊炎治疗市场的竞争格局

对黏液囊炎治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵黏液囊炎治疗市场供应商的绩效评估

FPNV定位矩阵是评估黏液囊炎治疗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了黏液囊炎治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对黏液囊炎治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告提供了涵盖关键重点领域的市场全面分析：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球肌肉骨骼疾病的发生率正在增加
      • 提高对卫生基础设施的认识和投资
    • 抑制因素
      • 政府对药品核准的严格规定
    • 机会
      • 黏液囊炎诊断工具和治疗方案的进展
      • 药物研发配方持续创新
    • 任务
      • 诊断复杂且缺乏报销政策
  • 市场区隔分析
    • 类型：慢性黏液囊炎有利于解决疼痛管理和预防进一步关节损伤的治疗
    • 最终使用者：医院和诊所可以轻鬆获得急性黏液囊炎所需的即时治疗。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章黏液囊炎治疗市场：依类型

  • 急性黏液囊炎
  • 黏液囊炎

第七章依药物类型分類的黏液囊炎治疗市场

  • 药物治疗
    • 皮质类固醇
    • 非类固醇消炎剂(NSAID)
    • 物理治疗
  • 物理治疗

第八章黏液囊炎治疗市场：依最终用户分类

  • 医院/诊所
  • 復健中心

第九章北美和南美黏液囊炎治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太黏液囊炎治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的黏液囊炎治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 远藤製药推出非专利药 Duexis“Ibuprofen/法莫替丁片”
    • FDA核准创新皮质类固醇治疗Duchenne氏肌肉失养症
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Amgen Inc.
  • Arinna Lifesciences Ltd.
  • AstraZeneca PLC
  • Bioanalytical Systems, Inc.
  • Bristol-Myers Squibb Company
  • Crescent Formulations Pvt.Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • NIDEK CO., LTD.
  • Novartis AG
  • Perrigo Company PLC
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Topcon Corporation
Product Code: MRR-5D693B46C73C

The Bursitis Treatment Market was valued at USD 7.81 billion in 2023, expected to reach USD 8.14 billion in 2024, and is projected to grow at a CAGR of 4.58%, to USD 10.69 billion by 2030.

The market for bursitis treatment encompasses a range of therapeutic approaches aimed at alleviating the inflammation and pain associated with bursitis, a condition where bursae-the small, fluid-filled sacs cushioning bones, tendons, and muscles near joints-become inflamed. The necessity for bursitis treatment arises from the need to manage pain and prevent further joint damage, thereby maintaining mobility and quality of life for sufferers. Applications of treatment span from pharmacological therapies, such as non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid injections, to physical therapy and surgery in severe cases. End-use scope is primarily in healthcare settings, including hospitals, clinics, and specialized orthopedic and physiotherapy centers.

KEY MARKET STATISTICS
Base Year [2023] USD 7.81 billion
Estimated Year [2024] USD 8.14 billion
Forecast Year [2030] USD 10.69 billion
CAGR (%) 4.58%

In terms of market growth, increasing incidences of lifestyle-related disorders, rising geriatric population, and greater public awareness of musculoskeletal health drive the demand for effective bursitis treatments. Latest opportunities include the development of advanced biologic therapies and minimally invasive surgical procedures that offer promising benefits in terms of efficacy and patient recovery time. Innovations in personalized medicine, driven by advances in genetic and biomarker research, may also provide targeted therapeutic options, addressing individual patient needs more precisely.

However, market growth is challenged by limitations such as the high costs associated with advanced therapies and the potential side effects of long-term pharmacological treatment. Restricted access to healthcare services in low-income regions further constrains market expansion. Additionally, regulatory hurdles and the slow pace of drug approval can delay the introduction of novel treatments.

Areas ripe for innovation and research include enhancing drug delivery systems to improve targeting and efficacy, developing cost-effective biologics, and integrating digital health solutions such as wearables for monitoring and managing bursitis symptoms. A focus on preventative care through ergonomic education and early intervention strategies also represents a significant avenue for business growth. The market displays a dynamic nature, characterized by rapid technological advancements and growing integration of interdisciplinary approaches in treatment and management strategies.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bursitis Treatment Market

The Bursitis Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidence of musculoskeletal disorders globally
    • Increased awareness coupled with rising investment in health infrastructure
  • Market Restraints
    • Strict government regulations regarding drug approval
  • Market Opportunities
    • Advancements in diagnostic tools and treatment options in bursitis
    • Ongoing innovation in drug development formulations
  • Market Challenges
    • Complexities associated with diagnostic and lack of reimbursement policies

Porter's Five Forces: A Strategic Tool for Navigating the Bursitis Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bursitis Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bursitis Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bursitis Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bursitis Treatment Market

A detailed market share analysis in the Bursitis Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bursitis Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bursitis Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bursitis Treatment Market

A strategic analysis of the Bursitis Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bursitis Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Arinna Lifesciences Ltd., AstraZeneca PLC, Bioanalytical Systems, Inc., Bristol-Myers Squibb Company, Crescent Formulations Pvt.Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., NIDEK CO., LTD., Novartis AG, Perrigo Company PLC, Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., and Topcon Corporation.

Market Segmentation & Coverage

This research report categorizes the Bursitis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Acute Bursitis and Chronic Bursitis.
  • Based on Drug Type, market is studied across Medication and Physical Therapy. The Medication is further studied across Corticosteroids, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), and Physical Therapy.
  • Based on End-User, market is studied across Hospitals & Clinics and Rehabilitation Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of musculoskeletal disorders globally
      • 5.1.1.2. Increased awareness coupled with rising investment in health infrastructure
    • 5.1.2. Restraints
      • 5.1.2.1. Strict government regulations regarding drug approval
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in diagnostic tools and treatment options in bursitis
      • 5.1.3.2. Ongoing innovation in drug development formulations
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities associated with diagnostic and lack of reimbursement policies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Chronic bursitis prefer treatments to address pain management and prevention of further joint damage
    • 5.2.2. End-User: Hospitals and clinics offer better accessibility for the immediate care required for acute bursitis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bursitis Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Acute Bursitis
  • 6.3. Chronic Bursitis

7. Bursitis Treatment Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Medication
    • 7.2.1. Corticosteroids
    • 7.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • 7.2.3. Physical Therapy
  • 7.3. Physical Therapy

8. Bursitis Treatment Market, by End-User

  • 8.1. Introduction
  • 8.2. Hospitals & Clinics
  • 8.3. Rehabilitation Centers

9. Americas Bursitis Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Bursitis Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Bursitis Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Endo Pharmaceuticals Introduces Generic Version of Duexis: Ibuprofen-Famotidine Tablets
    • 12.3.2. FDA Greenlights Innovative Corticosteroid for Duchenne Muscular Dystrophy Management
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. Arinna Lifesciences Ltd.
  • 4. AstraZeneca PLC
  • 5. Bioanalytical Systems, Inc.
  • 6. Bristol-Myers Squibb Company
  • 7. Crescent Formulations Pvt.Ltd.
  • 8. Eli Lilly and Company
  • 9. F. Hoffmann-La Roche Ltd.
  • 10. GlaxoSmithKline plc
  • 11. Johnson & Johnson Services, Inc.
  • 12. Merck & Co., Inc.
  • 13. NIDEK CO., LTD.
  • 14. Novartis AG
  • 15. Perrigo Company PLC
  • 16. Pfizer Inc.
  • 17. Sanofi S.A.
  • 18. Sun Pharmaceutical Industries Limited
  • 19. Teva Pharmaceutical Industries Ltd.
  • 20. Topcon Corporation

LIST OF FIGURES

  • FIGURE 1. BURSITIS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. BURSITIS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BURSITIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES BURSITIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES BURSITIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. BURSITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. BURSITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BURSITIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BURSITIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BURSITIS TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ACUTE BURSITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CHRONIC BURSITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES BURSITIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. BURSITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 189. BURSITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023